Alexandria Forbes Sells 35,839 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Alexandria Forbes sold 35,839 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the transaction, the chief executive officer now directly owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

MeiraGTx Trading Down 2.4 %

Shares of NASDAQ MGTX opened at $6.20 on Friday. The business has a fifty day moving average price of $6.29 and a 200 day moving average price of $5.14. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $7.37. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. The stock has a market capitalization of $484.55 million, a P/E ratio of -5.12 and a beta of 1.26.

Institutional Trading of MeiraGTx

Several hedge funds have recently modified their holdings of MGTX. JPMorgan Chase & Co. raised its stake in shares of MeiraGTx by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock worth $1,429,000 after acquiring an additional 4,186 shares in the last quarter. Garden State Investment Advisory Services LLC acquired a new position in shares of MeiraGTx during the third quarter worth $1,636,000. Barclays PLC lifted its holdings in shares of MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after purchasing an additional 76,437 shares during the last quarter. State Street Corp boosted its position in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after purchasing an additional 5,251 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in MeiraGTx during the 3rd quarter worth $2,795,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MGTX. Royal Bank of Canada increased their target price on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and set a $36.00 price objective on shares of MeiraGTx in a research note on Monday, November 18th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.